María Varela, MD, PhD, discusses the findings from a real-life analysis to confirm the benefit of regorafenib as treatment of patients with hepatocellular carcinoma who have progressed on prior sorafenib. Regorafenib was approved by the FDA for second-line treatment in this patient population based on data from the phase III RESORCE trial.
María Varela, MD, PhD, a pathologist in the Liver Unit at the Hospital Universitario Central de Asturias, discusses the findings from a real-life analysis to confirm the benefit of regorafenib (Stivarga) as treatment of patients with hepatocellular carcinoma (HCC) who have progressed on prior sorafenib (Nexavar). Regorafenib was approved by the FDA for second-line treatment in this patient population based on data from the phase III RESORCE trial.
If patients with HCC moved to regorafenib at the time of radiographic progression, they obtained better survival with regorafenib than if they stayed on sorafenib, Varela says. The survival for second-line regorafenib was estimated at 28 months versus 8 months with sorafenib, according to Varela.
There is some bias inthis real-life observational cohort
Integrating New Therapies With Autologous Stem Cell Transplant in Myeloma
March 26th 2024Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed how the role of autologous stem cell transplant is evolving in the myeloma treatment landscape with the emergence of CAR T-cell therapies and bispecifics.
Read More